|
BMS to Pay Isis $6 Million for Regulatory Filings
Isis Pharmaceuticals has earned a $6 million milestone payment from Bristol-Myers Squibb (BMS) for successful initial regulatory filings to begin Phase
I testing of an experimental cholesterol drug.
This article is viewable by subscribers only. To view this article, please select an option below.
|
|
Subscribe
Archives